Aquablation Therapy Triumphs at EAU 2025: A New Era in BPH Treatment
SAN JOSE, Calif. – PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is thrilled to share groundbreaking results from the WATER III trial, an independent study that puts Aquablation therapy at the forefront of treatment for benign prostatic hyperplasia (BPH). At the recent European Association of Urology (EAU) Congress, held in Madrid, these results were showcased during a high-profile session, underscoring their significance in urological care.
Understanding the WATER III Trial
The WATER III trial, which represents an international collaboration, involved a prospective, multicenter study comparing Aquablation therapy against traditional laser enucleation techniques for prostates sized between 80 and 180mL. Conducted from December 2020 through September 2024, the trial treated 186 men and assessed key outcomes at the three-month mark. Importantly, this study is set to follow participants for five years to further validate the long-term efficacy and safety of Aquablation therapy.
Key Findings and Outcomes
Results from the trial highlighted that Aquablation therapy demonstrated comparable symptom relief to laser enucleation while significantly reducing the risk of ejaculatory dysfunction, which was recorded at just 14.8% compared to 77.1% for laser techniques. Additionally, the rates of stress incontinence were impressively low at 0% versus 9.1% for laser enucleation. Most notably, the transfusion rate associated with Aquablation therapy was 0%, emphasizing its safety and the reliable management of bleeding risks.
Expert Insights on Aquablation Therapy
Reza Zadno, CEO of PROCEPT BioRobotics, expressed enthusiasm about the implications of the WATER III trial results: "WATER III represents a significant milestone in our mission to establish Aquablation therapy as the standard of care for patients suffering with BPH. These findings not only reinforce our commitment to providing effective treatments but also highlight Aquablation's ability to deliver significant clinical outcomes while preserving essential quality of life factors like sexual function and continence."
The Clinical Significance of Aquablation Therapy
Dr. Naeem Bhojani from the University of Montreal added, "The results are compelling, showing that Aquablation therapy can achieve outcomes comparable to those reached by highly skilled laser enucleation surgeons. The lower rates of ejaculatory dysfunction and stress incontinence represent significant advancements for patients seeking effective BPH treatments." This therapy's promise lies in its robust clinical foundation that showcases its effectiveness across a variety of prostate sizes.
Innovative Technology Behind Aquablation Therapy
Aquablation therapy is recognized as the first and only ultrasound-guided, robotic-assisted approach utilizing a heat-free waterjet for treating BPH. The technology offers surgeons a comprehensive view of the prostate, allowing for highly tailored treatment plans based on each individual’s anatomy. This precision is paramount; surgeons can target specific areas for removal while carefully preserving the nerves responsible for erectile and ejaculatory functions.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is dedicated to transforming patient care through cutting-edge urological solutions. They manufacture the advanced AQUABEAM® and HYDROS™ robotic systems. The HYDROS system stands out as the only artificial intelligence-powered technology designed specifically for delivering Aquablation therapy. With BPH impacting approximately 40 million men in the U.S., the company’s commitment to advancing treatment options is more vital than ever.
Commitment to Safety and Innovation
While all surgical treatments carry inherent risks, the extensive clinical literature surrounding Aquablation therapy, complemented by over 150 peer-reviewed publications, solidifies its potential as the leading treatment option for men with lower urinary tract symptoms due to BPH. PROCEPT BioRobotics is unwavering in its goal to enhance patient outcomes, ensuring both efficacy and safety across their urological innovations.
Frequently Asked Questions
What is Aquablation therapy?
Aquablation therapy is a robotic-assisted treatment that uses a heat-free waterjet to perform prostate surgery, specifically aimed at men suffering from BPH.
How does Aquablation therapy compare to laser enucleation?
Aquablation therapy has shown comparable symptom relief to laser enucleation but with lower rates of adverse events like ejaculatory dysfunction and urinary incontinence.
What are the main findings of the WATER III trial?
The trial found that Aquablation therapy effectively relieves BPH symptoms while maintaining higher quality of life with significantly fewer complications.
Is Aquablation suitable for all prostate sizes?
Yes, Aquablation therapy is effective for a range of prostate sizes, including those over 80 mL.
How can one learn more about PROCEPT BioRobotics?
For more information, you can reach out directly to PROCEPT BioRobotics through their marketing and investor relations contacts.
